Transcriptomic study of gastrointestinal stromal tumors with liver metastasis

Introduction: GIST (gastrointestinal stromal tumor) is the most prominent mesenchymal neoplasms of the gastrointestinal tract, and liver is the most common metastasis site for GIST. The molecular mechanism leading to liver metastasis of GIST is currently unclear.Methods: With the goal of revealing the underlying mechanism, we performed whole-genome gene expression profiling on 18 pairs of RNA samples comprised of GIST tissues (with liver metastasis) and corresponding non-tumor tissues. After identifying differentially expressed gene, functional annotation and signal pathway analyses were conducted. GSE13861, datasets that compare GIST (without liver metastasis) with adjacent tissues, served as a comparison.Results: A total of 492 up-regulated genes and 629 down-regulated genes were identified as differentially expressed genes between liver metastasis tissues and non-tumor tissues. We characterized expression patterns of DEGs identified from our cohort and GSE13861 that show signatures of enrichment for functionality. In subsequent gene set enrichment analysis, differentially expressed genes were mainly enriched in Epithelial Mesenchymal Transition in both datasets. 493 genes were overlapped among our whole-genome gene expression profiling results and GSE13861, consisting 188 up-regulated genes and 305 down-regulated genes. By using CytoHubba plugin of Cytoscape, CDH1, CD34, KIT, PROM1, SOX9, FGF2, CD24, ALDH1A1, JAG1 and NES were identified as top ten hub genes in tumorigenesis and liver metastasis of GIST. higher expression levels of FGF2, JAG1, CD34, ALDH1A1 and the lower expression level of CDH1 were respectively associated with unfavorable overall survival. Meanwhile higher expression levels of CD34, FGF2, KIT, JAG1, ALDH1A were correlated with worse disease-free survival.Discussion: The present study may help to provide candidate pathways and targets for treatment of GIST and prevention methods to liver metastasis.

[1]  C. Maher,et al.  Long noncoding RNAs in cancer metastasis , 2021, Nature Reviews Cancer.

[2]  D. Saini,et al.  Extracellular Matrix Remodeling and Development of Cancer , 2020, Stem Cell Reviews and Reports.

[3]  J. Haybaeck,et al.  Therapeutic Potential of PI3K/AKT/mTOR Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress , 2020, Cancers.

[4]  S. Sleijfer,et al.  Non-Coding RNAs, a Novel Paradigm for the Management of Gastrointestinal Stromal Tumors , 2020, International journal of molecular sciences.

[5]  S. George,et al.  Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade , 2020, Clinical Cancer Research.

[6]  T. Sugino,et al.  Driver gene alterations and activated signaling pathways toward malignant progression of gastrointestinal stromal tumors , 2019, Cancer science.

[7]  M. Paolillo,et al.  Extracellular Matrix Alterations in Metastatic Processes , 2019, International journal of molecular sciences.

[8]  S. Sleijfer,et al.  Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs , 2019, Cancers.

[9]  A. E. del Río Hernández,et al.  Role of Extracellular Matrix in Development and Cancer Progression , 2018, International journal of molecular sciences.

[10]  M. Heinrich,et al.  Translational insights into gastrointestinal stromal tumor and current clinical advances , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  D. Cantrell,et al.  Signaling and Function of Interleukin-2 in T Lymphocytes. , 2018, Annual review of immunology.

[12]  R. DeMatteo,et al.  ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor , 2017, Oncotarget.

[13]  J. Martín-Broto,et al.  GEIS guidelines for gastrointestinal sarcomas (GIST). , 2017, Cancer treatment reviews.

[14]  Damian Szklarczyk,et al.  The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..

[15]  Y. Shan,et al.  KIT Exon 11 Codons 557–558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors , 2016, Clinical Cancer Research.

[16]  Chung-Yen Lin,et al.  cytoHubba: identifying hub objects and sub-networks from complex interactome , 2014, BMC Systems Biology.

[17]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[18]  Jing Yang,et al.  Epithelial–mesenchymal plasticity in carcinoma metastasis , 2013, Genes & development.

[19]  Heikki Joensuu,et al.  Gastrointestinal stromal tumour , 2013, The Lancet.

[20]  Shreyaskumar R Patel.  Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway , 2013, Current Oncology Reports.

[21]  W. Leonard,et al.  Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. , 2013, Immunity.

[22]  Aki Vehtari,et al.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.

[23]  M. Heinrich,et al.  Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.

[24]  Jae Yong Cho,et al.  Gene Expression Signature–Based Prognostic Risk Score in Gastric Cancer , 2011, Clinical Cancer Research.

[25]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[26]  Stuart Thomson,et al.  A systems view of epithelial–mesenchymal transition signaling states , 2010, Clinical & Experimental Metastasis.

[27]  C. Antonescu,et al.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours , 2010, Nature.

[28]  C. Rocha-Lima,et al.  Molecular basis and management of gastrointestinal stromal tumors. , 2010, World journal of gastroenterology.

[29]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[30]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[31]  W. Jiang,et al.  Loss of tight junction barrier function and its role in cancer metastasis. , 2009, Biochimica et biophysica acta.

[32]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[33]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[34]  Y. Oda,et al.  Inverse relationship between E-cadherin and p27Kip1 expression in renal cell carcinoma. , 2008, International journal of oncology.

[35]  M. Heinrich,et al.  Molecular pathobiology of gastrointestinal stromal sarcomas. , 2008, Annual review of pathology.

[36]  R. DeMatteo,et al.  Combined Surgical and Molecular Therapy: The Gastrointestinal Stromal Tumor Model , 2006, Annals of surgery.

[37]  Kazuhiro Yoshida,et al.  Deletion of the KIT gene is associated with liver metastasis and poor prognosis in patients with gastrointestinal stromal tumor in the stomach. , 2006, International journal of oncology.

[38]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[40]  G. Christofori,et al.  Multitasking in Tumor Progression: Signaling Functions of Cell Adhesion Molecules , 2004, Annals of the New York Academy of Sciences.

[41]  Gerhard Christofori,et al.  Cell adhesion and signalling by cadherins and Ig-CAMs in cancer , 2004, Nature Reviews Cancer.

[42]  M. Zöller,et al.  The association of the tetraspanin D6.1A with the α6β4 integrin supports cell motility and liver metastasis formation , 2003, Journal of Cell Science.

[43]  W. Jiang,et al.  E-cadherin complex and its abnormalities in human breast cancer. , 2000, Surgical oncology.

[44]  Joseph Wang.  SURVEY AND SUMMARY From DNA biosensors to gene chips , 2000 .

[45]  R. DeMatteo,et al.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.

[46]  K. Matsumoto,et al.  Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells , 1999, Journal of cellular physiology.

[47]  S. Tsukita,et al.  Occludin and claudins in tight-junction strands: leading or supporting players? , 1999, Trends in cell biology.

[48]  I. Zvibel,et al.  Hepatocyte extracellular matrix modulates expression of growth factors and growth factor receptors in human colon cancer cells. , 1998, Experimental cell research.

[49]  Robert S. Kerbel,et al.  E-Cadherin–dependent Growth Suppression is Mediated by the Cyclin-dependent Kinase Inhibitor p27KIP1 , 1998, The Journal of cell biology.

[50]  C. Martínez-A,et al.  Intermediate Affinity Interleukin-2 Receptor Mediates Survival via a Phosphatidylinositol 3-Kinase-dependent Pathway* , 1997, The Journal of Biological Chemistry.

[51]  B. Gumbiner,et al.  A Synthetic Peptide Corresponding to the Extracellular Domain of Occludin Perturbs the Tight Junction Permeability Barrier , 1997, The Journal of cell biology.

[52]  W. Birchmeier,et al.  Expression of E-cadherin and catenins in invasive mammary carcinomas. , 1997, Anticancer research.

[53]  S. McKnight,et al.  Identification and purification of human Stat proteins activated in response to interleukin-2. , 1995, Immunity.

[54]  W. Leonard,et al.  The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. , 1995, Immunity.

[55]  E. Atkinson,et al.  Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. , 1992, Annals of surgery.

[56]  R. Gallo,et al.  Selective in vitro growth of T lymphocytes from normal human bone marrows. , 1976, Science.